Interesting ImagesComparison of 68Ga-PSMA PET/CT and Contrast-Enhanced MRI on Residual Disease Assessment of Juvenile Nasal AngiofibromaThakar, Alok MS*; Sakthivel, Pirabu MS, DNB*; Prashanth, Arun DM†; Bhalla, Ashu Seith MD‡; Sharma, Suresh Chandra MS*; Kumar, Rakesh MD†Author Information From the Departments of *Otorhinolaryngology & Head and Neck Surgery †Nuclear Medicine ‡Radiology, All India Institute of Medical Sciences, New Delhi, India. Received for publication October 6, 2019; revision accepted December 3, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Rakesh Kumar, MD, Division of Diagnostic Nuclear Medicine, Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi 110029, India. E-mail: email@example.com. Online date: February 12, 2020 Clinical Nuclear Medicine: April 2020 - Volume 45 - Issue 4 - p 308-309 doi: 10.1097/RLU.0000000000002951 Buy Metrics Abstract Prostate-specific membrane antigen (PSMA) is expressed in the endothelial cells of tumor-associated neovasculature of various nonprostatic benign and malignant neoplasms including juvenile nasopharyngeal angiofibroma (JNA). Positive uptake on PET/CT imaging with 68Ga-labeled PSMA is noted in a patient with residual disease after initial surgery without any abnormal uptake in postoperative fibrosis, in contrast to contrast-enhanced MRI, which was confirmed by biopsy. 68Ga-PSMA PET/CT may be a useful tool clinically for identifying early biochemical recurrences and in specifically differentiating recurrences from surgical site reparative tissue. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.